NEW YORK (GenomeWeb) – Atlas Genetics today announced it completed the final tranche of its £16.9 million ($28.4 million) Series B financing to complete the transfer to manufacture of its io molecular diagnostics system and file for regulatory approval of the first test for chlamydia.

Investors in the financing included Novartis Venture Funds, Consort Medical, Life Sciences Partners, BB Biotech Ventures, Johnson & Johnson Development, YFM Equity Partners, and private investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.